about
Cloning and characterization of cDNA for adenosine kinase from mammalian (Chinese hamster, mouse, human and rat) species. High frequency mutants of Chinese hamster ovary cells involve structural alterations in the geneAtezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.Analytical and preanalytical biases in serum proteomic pattern analysis for breast cancer diagnosis.Referral and treatment rates of neoadjuvant chemotherapy in muscle-invasive bladder cancer before and after publication of a clinical practice guidelineA multicentre analysis of abiraterone acetate in Canadian patients with metastatic castration-resistant prostate cancer.Treatment of muscle-invasive bladder cancer in Canada: A survey of genitourinary medical oncologists and urologists.Prognostic risk stratification derived from individual patient level data for men with advanced penile squamous cell carcinoma receiving first-line systemic therapy.Cisplatin-based first-line therapy for advanced urothelial carcinoma after previous perioperative cisplatin-based therapyPhase I study of the Hedgehog pathway inhibitor IPI-926 in adult patients with solid tumorsPrognostic and Predictive Factors in Patients with Advanced Penile Cancer Receiving Salvage (2nd or Later Line) Systemic Treatment: A Retrospective, Multi-Center Study.The future of systemic therapies for localised prostate cancer.Insulin-like growth factor binding protein-2 is a novel therapeutic target associated with breast cancer.Localized prostate cancer presenting as a renal pseudo-tumour.A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel.Clinical Outcomes of Perioperative Chemotherapy in Patients With Locally Advanced Penile Squamous-Cell Carcinoma: Results of a Multicenter Analysis.Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients.Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c.Cisplatin- Versus Non-Cisplatin-based First-Line Chemotherapy for Advanced Urothelial Carcinoma Previously Treated With Perioperative Cisplatin.Reduction in serum clusterin is a potential therapeutic biomarker in patients with castration-resistant prostate cancer treated with custirsen.Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer.Tolerance of sunitinib in dialyzed patients with metastatic renal cell carcinoma.Evaluation of prostate-specific antigen response following cessation of abiraterone acetate: is there evidence for a withdrawal syndrome?Borealis-1: a randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancer.A prognostic model for stratifying clinical outcomes in chemotherapy-naive metastatic castration-resistant prostate cancer patients treated with abiraterone acetate.Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer.Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer.Gene Expression Profiling of Advanced Penile Squamous Cell Carcinoma Receiving Cisplatin-based Chemotherapy Improves Prognostication and Identifies Potential Therapeutic Targets.AR-V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone Acetate.Prostate cancer with tertiary Gleason pattern 5 in prostate needle biopsy: clinicopathologic findings and disease progression.A case report of enzalutamide administration in a dialysis-dependent patient with castration-resistant prostate cancer.The impact of time to metastasis on overall survival in patients with prostate cancer.A randomized phase II study of pelareorep and docetaxel or docetaxel alone in men with metastatic castration resistant prostate cancer: CCTG study IND 209.Sunitinib maintenance therapy after response to docetaxel in metastatic castration resistant prostate cancer (mCRPC).A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195.Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study.Clinical effectiveness of docetaxel for castration-sensitive prostate cancer in a real-world population-based analysisA retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancerOutcomes with Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Who Have Poor Performance StatusPalliative radiotherapy improves pain and reduces functional interference in patients with painful bone metastases: a quality assurance studyA phase 2 study of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Canadian Urologic Oncology Group study P07a
P50
Q28573462-93A83286-9797-4B49-865F-932AB8580715Q30275266-02760C24-0928-4B80-8A0B-56F33CA46ADFQ33216932-B21C2F1E-5E93-4796-B900-9B8955806502Q34023055-DF06AB8A-D271-40D8-AE6B-8EF15E8AFB5AQ34183632-2D55B9B9-8F12-4382-94A6-70872C1F443EQ34435978-4A8A862E-3E6C-45D3-9F6C-3F61A7297654Q35065896-075C207A-7DA6-42C1-990C-3F2243924B8BQ35771672-929C2A01-4703-4830-85EF-F9723E9758F4Q36959835-1EE2A97A-4800-457D-8A14-8968B0A1D7F6Q37516498-6AE17AC8-168A-42FF-948F-667327415A53Q38105420-52B8665D-0E2F-462C-A990-FA207965ACE8Q38359386-9D8098AD-DC7C-475C-9DF2-009A15005DE4Q38568096-E9D186FE-950E-47FE-AA03-87B88B2B80CAQ38664856-C46BC578-C780-48E6-9262-A60ED52B404BQ38888805-0818CD60-203D-4427-B445-0BEAD0F47D9AQ39160474-5699441C-C9E6-4EB2-B4CF-50B39375934EQ39262037-0B44D2F3-90A5-423C-8607-139FF93F0AADQ40294732-1308C220-A102-4D59-A8AE-C9C1312F69DFQ42685237-733A0B90-1C41-4933-9EC4-C22AE161348CQ42928474-C6EC24BD-7606-44D8-8E8C-248CDE4ABCB2Q43264897-1F6AABED-3827-4BAE-A8E9-3E9ED57AF528Q44222380-8E8ACB80-33FE-4527-AF12-7961E5C2D767Q47568177-B1CFDADA-99D5-4FCD-B2E8-5FAE6FFF90C8Q49579799-CA0962AE-1B47-4ADD-95A7-A4A4AC508F36Q49790156-1A8B1D25-77FB-4735-95CD-D051B454AB27Q50515553-FEC70773-5EC8-4E97-8F8E-CE0885EA623EQ52760827-6BC1EEE5-F1F6-4DB1-82E5-09B6A17A1628Q53058965-BDCFD4F0-F13B-4FFF-A73A-A98972BBE492Q53206934-B85646A5-4534-4919-AC59-0FE6355FF044Q53534465-F95DA46E-27C9-4670-B1D1-C44E9AD89694Q53705968-48F8B776-14A1-4992-B2BF-203A6E3FCFCDQ53706001-03369F82-E385-4A93-95B7-3A0181E3022BQ53772302-90C2EF3D-54F8-4987-817E-EA5458DBA9FCQ53842727-D3523682-36DA-4D47-B2BD-E20CCABA4841Q55519124-BBFBA829-1C85-4E2B-A0BD-0C1C02580B3AQ58109449-1F6D6A15-C73D-4301-A977-CE6F30139988Q61872184-ED100C8E-2E1D-42F3-9B2B-5F843D8968DAQ61872186-F06521FA-183C-4A3A-940E-FBFE5BDBEB38Q80254508-1A378BF1-9126-46BF-9E7D-796C2824E220Q84566910-8B0F2C8F-7E63-4F38-B996-C2FCEA7C66C9
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Bernhard Eigl
@ast
Bernhard Eigl
@en
Bernhard Eigl
@es
Bernhard Eigl
@nl
type
label
Bernhard Eigl
@ast
Bernhard Eigl
@en
Bernhard Eigl
@es
Bernhard Eigl
@nl
prefLabel
Bernhard Eigl
@ast
Bernhard Eigl
@en
Bernhard Eigl
@es
Bernhard Eigl
@nl
P106
P31
P496
0000-0003-1653-6929